Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Opus Genetics, Inc.IRD · Entity 5892 | Director | April 20, 2026 | April 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Opus Genetics, Inc.
Report date April 20, 2026 · Filed April 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 243,894 |
Reported balance
After 2026-04-20 transaction · row 1
1 source rowRow 1 · 2026-04-20 · Grant · Acquired 24,367 · Balance 243,894 F1: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2026 Filed Apr 22, 2026 20:30 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 24,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-001784 · form4.xml · nonDerivative · entry 1 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,894 F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| April 30, 2025 Filed May 2, 2025 21:04 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantStock Option (Right to Buy) · Derivative | 79,592 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000905148-25-001426 · form4.xml · derivative · entry 2 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,592 Underlying: Common Stock · 79,592 shares Expires 2035-04-29 F2 · derivative.exercise_date: The option will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| April 30, 2025 Filed May 2, 2025 21:04 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 79,504 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-001426 · form4.xml · nonDerivative · entry 1 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,527 F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:25 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option (Right to Buy) · Derivative | 35,181 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0000905148-24-001710 · form4.xml · derivative · entry 2 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,181 Underlying: Common Stock · 35,181 shares Expires 2034-06-10 F2 · derivative.exercise_date: The option will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:25 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 41,143 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001710 · form4.xml · nonDerivative · entry 1 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,023 F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:57 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 19,418 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-000491 · form4.xml · nonDerivative · entry 1 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,880 F1 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for 2024. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock for the 30 consecutive trading days ending on and including the last trading day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $2.81 per share, the average of the closing price of the common stock for the 30 consecutive trading days prior to January 1, 2024. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 22:48 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option · Derivative | 9,639 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0001140361-23-029021 · form4.xml · derivative · entry 2 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,639 Underlying: Common Stock · 9,639 shares Expires 2033-06-05 F2 · derivative.exercise_date: Will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 22:48 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 10,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-029021 · form4.xml · nonDerivative · entry 1 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,462 F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| April 19, 2023 Filed Apr 22, 2023 00:20 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 1,053 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-019676 · form4.xml · nonDerivative · entry 1 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,486 F1 · price: The Reporting Person was granted shares of common stock in lieu of incremental cash amounts for board services for 2023. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock for the 30 consecutive trading days ending on and including the last trading day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $4.27 per share, the average of the closing price of the common stock for the 30 consecutive trading days prior to April 19, 2023. Read SEC document |
| January 11, 2023 Filed Jan 12, 2023 22:28 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 16,267 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-001504 · form4.xml · nonDerivative · entry 1 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,433 F1 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for 2023. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock for the 30 consecutive trading days ending on and including the last trading day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $3.07 per share, the average of the closing price of the common stock for the 30 consecutive trading days prior to January 11, 2023. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 22:07 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 12,376 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-025289 · form4.xml · nonDerivative · entry 2 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,166 F2 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for the second half of 2022. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock for the 30 consecutive trading days ending on and including the last trading day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $2.02 per share, the average of the closing price of the common stock for the 30 consecutive trading days prior to July 1, 2022. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 22:07 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 6,335 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-025289 · form4.xml · nonDerivative · entry 1 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,790 F1 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for the second quarter of 2022. The number of shares of common stock was determined by dividing (A) the aggregate amount of the retainer paid for board services for such fiscal quarter, by (B) the fair market value of the common stock on the last day of the fiscal quarter (rounded down to the nearest whole share). The fair market value was $1.92 per share, the closing price of the common stock on June 30, 2022. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:01 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001140361-22-023049 · form4.xml · derivative · entry 1 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-12 F1 · derivative.exercise_date: Will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 13:16 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 3,395 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-013064 · form4.xml · nonDerivative · entry 1 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,455 F1 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for the first quarter of 2022. The number of shares of common stock was determined by dividing (A) the aggregate amount of the retainer paid for board services for such fiscal quarter, by (B) the fair market value of the common stock on the last day of the fiscal quarter (rounded down to the nearest whole share). The fair market value was $3.24 per share, the closing price of the common stock on March 31, 2022. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:01 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 2,949 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-000658 · form4.xml · nonDerivative · entry 1 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,060 F1 · price: The Reporting Person was granted common stock in lieu of cash for Q4 2021 Board services. The number of shares of Common Stock having an aggregate Fair Market Value equal to the aggregate amount of the Retainers for such fiscal quarter, determined by dividing (A) the aggregate amount of the Retainers by (B) the Fair Market Value of the Common Stock on last day of the fiscal quarter (rounded down to the nearest whole share). The Fair Market Value was $3.73 per share, the closing price of the Company's stock on December 31, 2021. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:02 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 2,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-033449 · form4.xml · nonDerivative · entry 1 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,111 F1 · price: The Reporting Person was granted common stock in lieu of cash for Q3 2021 Board services. The number of shares of Common Stock having an aggregate Fair Market Value equal to the aggregate amount of the Retainers for such fiscal quarter, determined by dividing (A) the aggregate amount of the Retainers by (B) the Fair Market Value of the Common Stock on last day of the fiscal quarter (rounded down to the nearest whole share). The Fair Market Value was $5.15 per share, the closing price of the Company's stock on September 30, 2021. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 20:02 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseCommon Stock | 20,000 | $4.57 | $91,400.00 |
DisclosureSEC source: 0001140361-21-030364 · form4.xml · nonDerivative · entry 1 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,976 F1 · price: The price represents the weighted average price of the multiple transactions reported on this line. The shares were purchased at prices ranging from $4.52 to $4.61. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:02 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 2,083 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-023335 · form4.xml · nonDerivative · entry 1 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,976 F1 · price: The Reporting Person was granted common stock in lieu of cash for Q2 2021 Board services. The number of shares of Common Stock having an aggregate Fair Market Value equal to the aggregate amount of the Retainers for such fiscal quarter, determined by dividing (A) the aggregate amount of the Retainers by (B) the Fair Market Value of the Common Stock on last day of the fiscal quarter (rounded down to the nearest whole share). The Fair Market Value was $5.28 per share, the closing price of the Company's stock on June 30, 2021. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:13 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.74 | $0.00 |
DisclosureSEC source: 0001140361-21-020419 · form4.xml · derivative · entry 1 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-07 F1 · derivative.exercise_date: Will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 21:47 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 1,893 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-011672 · form4.xml · nonDerivative · entry 1 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,893 F1 · price: The Reporting Person was granted common stock in lieu of cash for Q1 2021 Board services. The number of shares of Common Stock having an aggregate fair market value equal to the aggregate amount of the Retainers for such fiscal quarter, determined by dividing (A) the aggregate amount of the Retainers by (B) the Fair Market Value of the Common Stock on last day of the fiscal quarter (rounded down to the nearest whole share). The Fair Market Value was $5.81 per share, the closing price of the Company's stock on March 31, 2021. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 22:32 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001140361-20-025554 · form4.xml · derivative · entry 1 Benton Susan · CIK 0001373649 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-11-11 F1 · derivative.exercise_date: 16,666 shares vest each twelve month period ending October 31, 2021 and October 31, 2022 and the balance vest October 31, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.